Hikma Pharmaceuticals (LON:HIK) Hits New 52-Week Low – Time to Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) reached a new 52-week low on Thursday . The company traded as low as GBX 1,232 and last traded at GBX 1,233.20, with a volume of 6431144 shares. The stock had previously closed at GBX 1,249.

Wall Street Analyst Weigh In

Several research firms have commented on HIK. JPMorgan Chase & Co. cut their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday, November 7th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Berenberg Bank boosted their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,300 and gave the company a “buy” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft cut their target price on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating for the company in a research note on Friday, January 9th. Finally, Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 target price on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of GBX 2,326.

Hikma Pharmaceuticals Stock Down 0.1%

The stock has a market capitalization of £2.68 billion, a P/E ratio of 7.24, a P/E/G ratio of 2.38 and a beta of 0.65. The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 63.59. The firm’s fifty day moving average is GBX 1,525.33 and its 200-day moving average is GBX 1,622.75.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.